Medical Condition News

RSS

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.

31 Jan 2011

National Jewish Health scientists identify signaling pathway for ALI

Researchers at National Jewish Health have discovered a signaling pathway that is crucial to the devastating effects of acute lung injury. The data, obtained from cells, animals and ALI patients, suggest several potential therapeutic targets. Experimental blockade of one of the targets significantly reduced flooding of the lungs that is the hallmark of ALI.

31 Jan 2011

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

Maxygen, a biotechnology company focused on the development of improved protein drugs, today announced the initiation of a Phase I clinical study to evaluate a next-generation CTLA4-Ig therapeutic that is being developed by Perseid Therapeutics LLC, Maxygen's majority-owned subsidiary, in collaboration with Astellas Pharma Inc. for the treatment of rheumatoid arthritis and potentially other autoimmune indications.

31 Jan 2011

Loyola inaugurates clinic exclusively to treat children with headaches

Fortunately, in most cases the causes of childhood headaches are usually no cause for alarm, Schnitzler said. Children can get headaches from stress, anxiety, inadequate sleep, vision problems, caffeine or food sensitivities. To help pinpoint the cause, Loyola has opened a clinic that's exclusively devoted to treating children with headaches.

31 Jan 2011

Empire State Building, NYRR partner with MMRF for new myeloma drugs

For the first time in the 34-year history of the Empire State Building Run-Up, the New York Road Runners has partnered with a nonprofit as the event's Presenting Sponsor.

31 Jan 2011

Lowe's receives CEO Cancer Gold Standard accreditation

Lowe's has received CEO Cancer Gold Standard accreditation, recognizing the company's commitment to reducing the cancer risk of its employees and their families by encouraging healthy lifestyles and promoting early detection through screenings, and by providing quality care, including access to cancer clinical trials, when a cancer diagnosis becomes a reality.

31 Jan 2011

Physicians suggest new target structure for deep brain stimulation

Nearly ten percent of all cases of depression are so severe that the patients do not respond to any established treatment method. Targeted stimulation of areas in the brain using a type of "brain pacemaker" has recently raised hopes: According to initial studies, half of patients with the most severe depression treated in this manner see a significant improvement in mood.

31 Jan 2011

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.

31 Jan 2011

New study: FUS protein appears to inhibit growth of prostate cancer cells in lab

Cancer researchers have discovered an important protein, produced naturally inside cells, that appears to suppress the growth of prostate cancer cells in the laboratory. The findings, published tomorrow in the journal Cancer Research, offer promising leads for research towards new treatments.

31 Jan 2011

Scientists to commence new DNA vaccine trial for use in patients with leukemia

A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.

31 Jan 2011

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

Patients unaware of stroke risk with irregular heart beat conditions

Thousand of people who suffer from irregular heartbeats or conditions termed as arrhythmias are unaware they are at high risk of suffering a stroke. A new survey found that two of three people do not know the warning signs of shortness of breath and palpitations. Experts estimate that more than 4,000 strokes a year could be prevented by better awareness among the general public and doctors of the heart condition atrial fibrillation (AF) this manifests as palpitations and irregular heart beat.

31 Jan 2011

Extreme morning sickness drug comes at a price

Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.

31 Jan 2011

Sorin Group announces commercial availability of Perceval S aortic heart valve in Europe

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announces the commercial availability in Europe of the self- anchoring Perceval S aortic heart valve. The innovative next-generation valve represents the latest innovation in heart valve technology.

31 Jan 2011

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, is pleased to announce that the first group of patients receiving the lowest dose of SCIB1 in the Phase I clinical trial has been evaluated by the Cohort Review Committee.

31 Jan 2011

EU grants 3.3 million to AMP for gene therapy development against AIP

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the European Union has finalized a EUR 3.3 million grant to the AIPGENE consortium, of which AMT is a member, for the development of a gene therapy product for Acute Intermittent Porphyria.

31 Jan 2011

Venture philanthropist invests $3.5 million to thwart Alzheimer's disease

Retired San Francisco real estate developer Douglas Rosenberg says he has a new job - helping to find a cure for Alzheimer's disease. Through the Ellen and Douglas Rosenberg Foundation, the venture philanthropist is betting at least $3.5 million that Buck faculty Dale Bredesen, MD has the correct take on how to thwart the memory robbing disease that affects over 5 million Americans.

31 Jan 2011

New study: Super Bowl loss is linked to increased death rates in older individuals

A new study published in the journal Clinical Cardiology reveals that a Super Bowl loss for a home team was associated with increased death rates in both men and women and in older individuals.

31 Jan 2011

Omega-3 deficieny may play a role in neuropsychiatric disorders: Study

Researchers from Inserm and INRA and their collaborators in Spain collaboration, have studied mice fed on a diet low in omega-3 fatty acid. They discovered that reduced levels of omega-3 had deleterious consequences on synaptic functions and emotional behaviours.

30 Jan 2011

Blind individual drives street vehicle independently

The National Federation of the Blind, the oldest and largest organization of blind people in the nation, announced today that for the first time a blind individual has driven a street vehicle in public without the assistance of a sighted person.

30 Jan 2011

Medical Condition News

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

National Jewish Health scientists identify signaling pathway for ALI

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

Loyola inaugurates clinic exclusively to treat children with headaches

Empire State Building, NYRR partner with MMRF for new myeloma drugs

Lowe's receives CEO Cancer Gold Standard accreditation

Physicians suggest new target structure for deep brain stimulation

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

New study: FUS protein appears to inhibit growth of prostate cancer cells in lab

Scientists to commence new DNA vaccine trial for use in patients with leukemia

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Patients unaware of stroke risk with irregular heart beat conditions

Extreme morning sickness drug comes at a price

Sorin Group announces commercial availability of Perceval S aortic heart valve in Europe

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

EU grants 3.3 million to AMP for gene therapy development against AIP

Venture philanthropist invests $3.5 million to thwart Alzheimer's disease

New study: Super Bowl loss is linked to increased death rates in older individuals

Omega-3 deficieny may play a role in neuropsychiatric disorders: Study

Blind individual drives street vehicle independently

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News